EligibleTrials

Propofol: clinical trials recruiting now

15
Recruiting trials
15
Conditions studied
1
US states with sites
9
Countries

FDA drug label

FDA-approved
Yes. Propofol appears in the FDA drug-label database. Marketed as propofol.
Drug class
General Anesthetic (FDA established pharmacologic class)

FDA-approved use

Propofol injectable emulsion is an intravenous general anesthetic and sedation drug indicated for: Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients Sedation for Adult Patients in Combination with Regional Anesthesia Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients Limitations of Use Propofol injectable emulsion is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations [see Pediatric Use ( 8.4 )] . Safety, effectiveness and dosing guidelines for propofol injectable emulsion have not been established for MAC sedation in the pediatric population; therefore, it is not recommended for this use [see Pediatric Use ( 8.4 )]. Propofol injectable emulsion is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established [see Pediatric Use ( 8.4 )].…

FDA recalls / enforcement

Reason (FDA)ClassificationStatusInitiated
Presence of Particulate Matter; single visible particulate was identified during a retain sample inspection identified as stainless steel — Hospira Inc. Class II (FDA: may cause temporary or reversible harm) Terminated 2013-05-25
Presence of Particulate Matter: A single visible particulate was identified during a retain sample inspection. — Hospira Inc. Class II (FDA: may cause temporary or reversible harm) Terminated 2013-04-08
Presence of Particulate Matter: Glass defect located on the interior neck of the vial identified glass surface abrasions and visible embedded particulate matter which could result in the potential for small glass flakes or embedded metal particulate to become dislodged into the solution. — Hospira Inc. Class II (FDA: may cause temporary or reversible harm) Terminated 2013-12-12
Presence of Particulate Matter: Visible particulate embedded in the glass vial was observed and confirmed in a sample bottle during retain sample inspection. — Hospira Inc. Class II (FDA: may cause temporary or reversible harm) Terminated 2013-08-14
Temperature Abuse: Products experienced uncontrolled temperature excursions during transit. — Hospira Inc. Class I (FDA: reasonable probability of serious harm or death) Terminated 2014-10-06

FDA label via openFDA

Phase breakdown

Phase 2 1 Phase 4 7 Not applicable 7

Conditions being studied

ConditionTrials
Depression · Propofol for Depression4
Anesthesia · Propofol for Anesthesia3
Lung Cancer · Propofol for Lung Cancer3
Obesity · Propofol for Obesity3
Chronic kidney disease1
Colonic Polyp1
Constipation1
Endometriosis1
Etomidate Combined With Propofol1
Femur Fracture1
General Anesthetic Drug Adverse Reaction1
Heart Arrhythmia1
Heart failure1
Hip Fractures1
Hypertension1

Recruiting trials involving Propofol

Common questions

Is Propofol FDA-approved?

Yes, marketed as propofol.

How many recruiting trials involve Propofol?

15 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.